Cytokinetics, Incorporated

CYTK

NASDAQ

Healthcare

Biotechnology

South San Francisco, CA, US498 employeescytokinetics.com

$66.61

-0.01(-0.02%)

Mkt Cap $8.2B

$29.84

$70.10

52-Week Range

At a Glance

AI-generated

Revenue breakdown: License And Milestone Revenues (86.7%), Collaboration Revenues (13.3%).

8-K

Cytokinetics, Incorporated announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity.

$8.2B

Market Cap

$89M

Revenue

-$792M

Net Income

Employees498

Fundamentals

How The Business Makes Money

Revenue by Segment

License And Milestone Revenues86.7%($192M)

Collaboration Revenues13.3%($30M)

Revenue by Geography

CN100%($5M)

Activity

What Changed Recently

Financial Results

Feb 23, 2026

and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any

Other Event

Feb 16, 2026

Other Events. Cytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets fo

Peer Companies

Company	Price	Change	Market Cap	P/E
JAZZJazz Pharmaceuticals plc	$186.84	-0.76%	$11.5B	-31.2
AXSMAxsome Therapeutics, Inc.	$168.22	-2.07%	$8.6B	-43.4
ABVXAbivax S.A.	$118.21	+2.82%	$7.8B	-33.0
NUVLNuvalent, Inc.	$105.04	-0.57%	$7.7B	-17.0
HALOHalozyme Therapeutics, In...	$64.47	-1.42%	$7.6B	23.3
MTSRMTSR	$70.50	-0.35%	$7.4B	—
MRUSMRUS	$90.00	+0.00%	$6.8B	—
RYTMRhythm Pharmaceuticals, I...	$86.33	-2.04%	$5.9B	-28.8

Analyst View

Company Profile

CIK0001061983

ISINUS23282W6057

CUSIP23282W605

Phone650 624 3000

Address350 Oyster Point Boulevard, South San Francisco, CA, 94080, US

SEC EDGAR